WASHINGTON, D.C. (July 1, 1998) - At its annual membership meeting June 16, 1998 in New York City, the Biotechnology Industry Organization (BIO) elected 13 new members to its Board of Directors. Each new board member is elected to a one-year term, effective July 1, and will be eligible for reelection to serve three consecutive terms.
"The new BIO Board of Directors brings vision, vitality and breadth of experience to the leadership of the biotechnology industry," said BIO President Carl B. Feldbaum. "This is the group that will lead the biotechnology industry into the next century and an era of quite remarkable biomedical, industrial and agricultural breakthroughs."
The new members of the BIO Board of Directors are Simon G. Best, CEO, Roslin Bio-med/PPL Therapeutics; Donald L. Drakeman, J.D., Ph.D., President and CEO, Medarex, Inc.; Ronald W. Eastman, CEO and President, Geron Corporation; Janet E. Haskell, President, Myriad Genetic Laboratories, Inc.; John A. Irick, President and CEO, Apex Bioscience, Inc.; Rachel K. King, CEO, Genetic Therapy, Inc.; Kurt M. Landgraf, Executive Vice President, E.I. du Pont de Nemours & Company; Alex McPherson, M.D., Ph.D., President and CEO, Biomira, Inc.; Joseph A. Mollica, Ph.D., Chairman and CEO, Pharmacopeia, Inc.; George B. Rathmann, Chairman and CEO, ICOS Corporation; Una S. Ryan, Ph.D., President and CEO, T Cell Sciences, Inc.; Frederick Telling, Vice President, Corporate Strategic Planning and Policy, Pfizer Inc; John Walker, Chairman, AxyS Pharmaceuticals, Inc.
The Biotechnology Industry Organization (BIO) represents over 780 biotechnology companies, academic institutions and state biotechnology centers in 46 states and 25 nations. BIO members are involved in the research and development of health care, agricultural and environmental biotechnology products.